Skip to main content
Marc Sabatine, MD, Cardiology, Boston, MA

MarcSabatineMD

Cardiology • Boston, MA

Adult Congenital Heart Disease

Associate Professor of Medicine, Brigham and Women's Hospital.

Join to view full profile

Dr. Sabatine is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Sabatine's full profile

Already have an account?

  • Office

    75 Francis St
    Brigham And Womens Hospital Cardiovascular Division
    Boston, MA 02115
    Phone+1 617-278-0145

Summary

  • Dr. Marc Sabatine is a cardiologist located in Boston, MA. He graduated from Harvard Medical School in 1995 and completed his residency and fellowship in cardiovascular disease at Massachusetts General Hospital (MGH). He attends in the cardiac intensive care units at both Brigham and Women's Hospital and MGH. He is the Chair of the TIMI Study Group, the oldest cardiovascular academic research organization in North America. To that end, Dr. Sabatine has been the Study Chair for multiple practice-changing, large-scale, international, randomized controlled trials of novel antithrombotic, lipid-lowering, anti-diabetes and other pharmacotherapies. Dr. Sabatine has authored over 400 papers, including in the New England Journal of Medicine, JAMA, and the Lancet. He has been recognized as one of the most highly cited researchers in medicine for many years running. He is a Fellow of the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. He has been inducted into the American Society of Clinical Investigation, the Interurban Clinical Club, and the Association of University Cardiologists.

Education & Training

  • Massachusetts General Hospital
    Massachusetts General HospitalFellowship, Cardiovascular Disease, 1995 - 2002
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 1995 - 1998
  • Harvard Medical School
    Harvard Medical SchoolClass of 1995

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2000 - 2025
  • Cardiovascular Disease
    American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 2012
  • Fellow (FACC) American College of Cardiology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients with Heart Failure with Reduced Ejection Fraction  
    Mikhail N Kosiborod, Marc S Sabatine, JAMA Cardiology
  • Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction with Statins, Ezetimibe, and PCSK9 Inhibition  
    Robert P Giugliano, Marc S Sabatine, JAMA Cardiology
  • PCSK9 Inhibition—A Tale of 2 Potential Treatment Opportunities—Reply  
    Brian A Bergmark, Marc S Sabatine, JAMA Cardiology
  • Join now to see all

Lectures

  • PCSK9 Inhibitors: What We Know What We Don't Know and Where are We Going? 
    2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019

Authored Content

  • Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin TherapyAugust 2020
  • Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin TherapyAugust 2020
  • Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol GuidelinesAugust 2020
  • Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial InfarctionMay 2020
  • Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial InfarctionMay 2020
  • Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients with Multivessel Coronary DiseaseJanuary 2018
  • Reply Cost-Effectiveness of Long-Term Ticagrelor in Patients with Prior Myocardial Infarction: Analysis by SubgroupsJanuary 2018
  • Join now to see all

Press Mentions

  • First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
    First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current AnticoagulantsJanuary 3rd, 2023
  • Statins Boost Glycemia Slightly, but CVD Benefits Prevail
    Statins Boost Glycemia Slightly, but CVD Benefits PrevailNovember 14th, 2022
  • Amgen Presents New Repatha® (Evolocumab) Data at Aha 2022
    Amgen Presents New Repatha® (Evolocumab) Data at Aha 2022November 7th, 2022
  • Join now to see all

Committees

  • member, 2014 AHA/ACC NSTE-ACS Guideline

Professional Memberships

Dr. Marc Sabatine, Dr. Marc Sabatine, MD, Dr. M Sabatine